Barnett P G, Swindle R W
HSR&D Center for Health Care Evaluation, Veterans Affairs Palo Alto Health Care System, Menlo Park, CA, USA.
Health Serv Res. 1997 Dec;32(5):615-29.
To identify the characteristics of cost-effective inpatient substance abuse treatment programs.
DATA SOURCES/STUDY SETTING: A survey of program directors and cost and discharge data for study of 38,863 patients treated in 98 Veterans Affairs treatment programs.
We used random-effects regression to find the effect of program and patient characteristics on cost and readmission rates. A treatment was defined as successful if the patient was not readmitted for psychiatric or substance abuse care within six months.
Treatment was more expensive when the program was smaller, or had a longer intended length of stay (LOS) or a higher ratio of staff to patients. Readmission was less likely when the program was smaller or had longer intended LOS; the staff to patient ratio had no significant effect. The average treatment cost $3,754 with a 75.0% chance of being effective, a cost-effectiveness ratio of $5,007 per treatment success. A 28-day treatment program was $860 more costly and 3.3% more effective than a 21-day program, an incremental cost-effectiveness of $26,450 per treatment success. Patient characteristics did not affect readmission rates in the same way they affected costs. Patients with a history of prior treatment were more likely to be readmitted but their subsequent stays were less costly.
A 21-day limit on intended LOS would increase the cost-effectiveness of treatment programs. Consolidation of small programs would reduce cost, but would also reduce access to treatment. Reduction of the staff to patient ratio would increase the cost-effectiveness of the most intensively staffed programs.
确定具有成本效益的住院药物滥用治疗项目的特征。
数据来源/研究背景:对项目主任进行的一项调查以及98个退伍军人事务治疗项目中38863名患者的成本和出院数据。
我们使用随机效应回归来确定项目和患者特征对成本和再入院率的影响。如果患者在六个月内未因精神疾病或药物滥用护理而再次入院,则将治疗定义为成功。
当项目规模较小、预期住院时间(LOS)较长或工作人员与患者的比例较高时,治疗费用更高。当项目规模较小或预期住院时间较长时,再入院的可能性较小;工作人员与患者的比例没有显著影响。平均治疗费用为3754美元,治疗成功的概率为75.0%,每成功治疗一次的成本效益比为5007美元。一个为期28天的治疗项目比一个为期21天的项目成本高860美元,效果好3.3%,每成功治疗一次的增量成本效益为26450美元。患者特征对再入院率的影响与对成本的影响方式不同。有既往治疗史的患者更有可能再次入院,但他们随后的住院费用较低。
将预期住院时间限制在21天将提高治疗项目的成本效益。合并小型项目将降低成本,但也会减少治疗机会。降低工作人员与患者的比例将提高人员配备最密集项目的成本效益。